These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 33457424)

  • 1. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
    Yabiku K; Nakamoto K; Tsubakimoto M
    J Diabetes Res; 2020; 2020():1682904. PubMed ID: 33457424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
    Cho KY; Nakamura A; Omori K; Takase T; Miya A; Yamamoto K; Nomoto H; Kameda H; Taneda S; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Jul; 12(7):1272-1277. PubMed ID: 33131199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
    Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
    Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).
    Goto R; Kamimura K; Shinagawa-Kobayashi Y; Sakai N; Nagoya T; Niwa Y; Ko M; Ogawa K; Inoue R; Yokoo T; Sakamaki A; Kamimura H; Abe S; Nishina H; Terai S
    FEBS Open Bio; 2019 Apr; 9(4):643-652. PubMed ID: 30984539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
    Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study.
    Shin Y; Choi H; Lim S
    Diabetes Res Clin Pract; 2021 May; 175():108843. PubMed ID: 33933498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease.
    Nagoya T; Kamimura K; Goto R; Shinagawa-Kobayashi Y; Niwa Y; Kimura A; Sakai N; Ko M; Nishina H; Terai S
    FEBS Open Bio; 2019 Dec; 9(12):2016-2024. PubMed ID: 31561285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
    Tahara A
    Eur J Pharmacol; 2021 Jun; 901():174076. PubMed ID: 33798599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.
    Hazem RM; Ibrahim AZ; Ali DA; Moustafa YM
    Int Immunopharmacol; 2022 Mar; 104():108503. PubMed ID: 34998036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr
    Al-Sharea A; Murphy AJ; Huggins LA; Hu Y; Goldberg IJ; Nagareddy PR
    Atherosclerosis; 2018 Apr; 271():166-176. PubMed ID: 29518749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
    Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model.
    Lee YK; Oh TJ; Lee JI; Choi BY; Cho HC; Jang HC; Choi SH
    Eur J Pharmacol; 2023 Oct; 957():175946. PubMed ID: 37541370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model.
    Kimura A; Kamimura K; Ohkoshi-Yamada M; Shinagawa-Kobayashi Y; Goto R; Owaki T; Oda C; Shibata O; Morita S; Sakai N; Abe H; Yokoo T; Sakamaki A; Kamimura H; Terai S
    Biochem Biophys Res Commun; 2022 Mar; 596():76-82. PubMed ID: 35121372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice.
    Zhao DM; Li CQ; Sun YM; Fan JY; Wu N; Sun YN; Sun XY
    Endokrynol Pol; 2023; 74(2):190-196. PubMed ID: 37039492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.